Gestational Diabetes and Antenatal Human Milk Expression
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 246 people enrolled
- Started
- 10 May 2023
- Ended
- 10 May 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Antenatal milk expression and breastfeeding self-efficacy enhancement
- Record updated
- 19 September 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- diagnosed gestational diabetes without on insulin
- can read and speak Chinese
- Hong Kong resident and stay in Hong Kong after delivery
- no serious medical or obstetrical complications
- no mental health illness or history
- have regular antenatal check-up
- singleton pregnancy
- primiparous or multiparous women
- intention to breastfeed
- pre-pregnancy BMI<25
Who cannot take part
- do not have Hong Kong Identify Card
- breastfeeding elder child at pregnancy
- cannot understand the study
- give birth <37 weeks of gestation
- a known fetal anomaly or any suspicion of fetal compromise
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Exclusive breastfeeding is global recognized as the optimal infant feeding. Hong Kong is committed to promoting, protecting and supporting the global movement for successful breastfeeding. Exclusive breastfeeding is especially strongly recommended and supported to the maternal history of Gestational Diabetes Mellitus (GDM). This study aims to examine the acceptability and feasibility of Antenatal human milk expression (AME) as breastfeeding intervention to improve breastfeeding for GDM women. The efficacy of AME practice on the breastfeeding exclusivity will also be investigated. It is hypothesized that AME will increase breastfeeding exclusivity compare with women receiving standard care, and will improve the breastfeeding self-efficacy and reduce depressive symptoms of women after birth.
The 2 groups in the trial
- Standard care plus an antenatal milk expression educationTreatment being tested
Participants will have one face-to-face breastfeeding education in lactation clinic at 37 weeks of gestation and telephone follow-up weekly till delivery.
Treatment: Antenatal milk expression and breastfeeding self-efficacy enhancement
- Standard hospital antenatal careNo study treatment, for comparison
Participants will receive standard care include prenatal breastfeeding education at gestation of 24-36 weeks same as intervention group. They will not discuss about antenatal milk expression, breastfeeding self-efficacy and the effects of breastfeeding on GDM women.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Effects and Experience of a Gestational Diabetes and Antenatal Human Milk Expression (GAME) Programme in Hong Kong Chinese Women
- Publications
- Record updated
- 19 September 2024